Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности габапентина в терапии болевой формы диабетической нейропатии
Возможности габапентина в терапии болевой формы диабетической нейропатии
Е.В.Бирюкова. Возможности габапентина в терапии болевой формы диабетической нейропатии. Consilium Medicum. Неврология (Прил.). 2014; 2: 15-18.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Harati Y. Diabetes and the nervous system. Endocrinol Metab Clin North Am 1996; 25 (2): 325–59.
2. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21 (5): 527–33.
3. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–25.
4. Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007; 3 (6): 331–40.
5. Kempler P (ed.). Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
6. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews 1999; 7: 245–52.
7. Данилов А. Б., Давыдов О. С. Нейропатическая боль. М.: Боргес, 2007.
8. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47 (2): 123–8.
9. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9 (4): 301–14.
10. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1998; 15: 97–112.
11. DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12. EDIC: The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensivetherapy on microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563–9.
13. Левин О. С. Лечение болевого синдрома при полиневропатиях. Трудный пациент. 2007; 4: 27–32.
14. Bril V, England J, Franklin GM et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online: April 11, 2011.
15. Wiffen PJ, Collins S, McQuay HJ et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; 2: CD001133. DOI: 10.1002/14651858. CD001133.pub2. Available at: http://www.cochrane.org/reviews
16. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008; 31: S255–61.
17. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25 (1): 81–104.
18. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20 (4): 280–5.
19. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; CD007938 88.
20. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56–8.
21. Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233–49.
22. Табеева ГР., Азимова ЮЭ. Фармакотерапия невропатической боли. Фармакотерапия. Фарматека. 2011; 9: 12–6.
23. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94 (4): 1131–9.
2. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21 (5): 527–33.
3. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–25.
4. Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007; 3 (6): 331–40.
5. Kempler P (ed.). Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
6. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews 1999; 7: 245–52.
7. Данилов А. Б., Давыдов О. С. Нейропатическая боль. М.: Боргес, 2007.
8. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47 (2): 123–8.
9. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9 (4): 301–14.
10. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1998; 15: 97–112.
11. DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12. EDIC: The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensivetherapy on microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563–9.
13. Левин О. С. Лечение болевого синдрома при полиневропатиях. Трудный пациент. 2007; 4: 27–32.
14. Bril V, England J, Franklin GM et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online: April 11, 2011.
15. Wiffen PJ, Collins S, McQuay HJ et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; 2: CD001133. DOI: 10.1002/14651858. CD001133.pub2. Available at: http://www.cochrane.org/reviews
16. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008; 31: S255–61.
17. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25 (1): 81–104.
18. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20 (4): 280–5.
19. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; CD007938 88.
20. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56–8.
21. Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233–49.
22. Табеева ГР., Азимова ЮЭ. Фармакотерапия невропатической боли. Фармакотерапия. Фарматека. 2011; 9: 12–6.
23. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94 (4): 1131–9.
Авторы
Е.В.Бирюкова
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.